Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by bluemoons20on Mar 26, 2023 9:37pm
183 Views
Post# 35361618

Re: Flat lining

Re: Flat liningIn a way , this is probably not a real surprise!   For the past five years there has not really been any interest in this company  other than the few folks that comment on this board.

Very little volume  and of course the price direction does not scream out for selling.

Seem to recall when i  got in there were 17 million shares out  There were also these potential pathways to  profit.

Only  two  are being explored and Sheseido  is the only one that has anything undertaken in a 'real'  manner.  This was before  any mention of the DI.

Lets  hope  something  comes of the  arbitration.  there is not  much hope as I  can see otherwise.   Given the time that has past  , many  of the early investors have likely forgotten  about this  stock.   There has not  even been enough volume to lead you to believe people have written it off as a tax loss.

Guess we waira few more  months  and HOPE!

GLTA


<< Previous
Bullboard Posts
Next >>